Email Alert RSS
Turn off MathJax
Article Contents
Abstract
References
Related Articles
LIU Dan, LI Xiuqi, LIU Shupeng, WU Xiaofei, YU Mengyang, WANG Hongyun. Radionuclide Drug Conjugates： China's 15-Year Research and Development Process and Latest Policy Support[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0577
Citation: LIU Dan, LI Xiuqi, LIU Shupeng, WU Xiaofei, YU Mengyang, WANG Hongyun. Radionuclide Drug Conjugates： China's 15-Year Research and Development Process and Latest Policy Support[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0577
shu

Radionuclide Drug Conjugates： China's 15-Year Research and Development Process and Latest Policy Support

  • 1 Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs;

  • 2 State Key Laboratory of Complex Severe and Rare Diseases, Beijing 100730;

  • 3 ChinaShenyang Pharmaceutical University, School of Life Science and Biopharmaceuticals, Shenyang, 110000, China

Funds: 

Capital’s Funds for Health Improvement and Research (2022-2Z-4018)

More Information
  • Received Date: July 24, 2024
  • Available Online: September 20, 2024
    Graphical Abstract
    • Abstract
  • This manuscript provides a comprehensive and systematic retrospective review of the developmental milestones achieved in the field of Radionuclide Drug Conjugates (RDC) in China, spanning the period from 2009 to May 2024.The development of Radionuclide Drug Conjugates (RDCs) stands as a testament to cross-disciplinary collaboration, merging the realms of diagnostics and therapy into a cohesive treatment approach.Endowed with an ability for precise tumor targeting, coupled with superior diagnostic sensitivity and therapeutic profile, RDC has solidified its status as a potent agent with extensive application potential within the medical field, particularly excelling in the domains of oncology treatment and diagnostics.This article discusses the overview, structure and classification of RDC drugs, the trend of clinical research and progress of clinical trials in China, the current status of drug development and policy support, with the aim of providing certain references for researchers in related fields to promote the further development and application of RDC drugs.
    • FullText(HTML)
    • References (0)
    • Related Articles

  • Related Articles

    [1]ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605
    [2]TIAN Kunling, CHEN Chuanning. Notch Signaling Pathway and Congenital Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 649-654. DOI: 10.12290/xhyxzz.2023-0594
    [3]ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
    [4]LI Wendao, GU Hao, WANG Wei, WU Runhui, SONG Hongmei. First Case Report of FOXN1 Haploinsufficiency in China and Literature Review[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 366-372. DOI: 10.12290/xhyxzz.2022-0040
    [5]LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271
    [6]ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180
    [7]Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555
    [8]LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. DOI: 10.3969/j.issn.1674-9081.2020.00.019
    [10]Ming-sheng MA, Xü-de ZHANG, Min WEI, Shi-min ZHAO, Zheng-qing QIU. Efficacy of Low Dose Corticosteroid Therapy in Duchenne Muscular Dystrophy[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(4): 384-388. DOI: 10.3969/j.issn.1674-9081.2014.04.006

  • Cited by

    Periodical cited type(28)

    1. 彭晓艳，陈朝英，涂娟，高洁，李华荣. 儿童肾小管酸中毒的临床特点及诊治. 中国医刊. 2025(01): 74-78 .
    2. 辛宇，徐俊杰，臧丽. Gitelman综合征导致糖代谢异常的相关因素分析. 中华糖尿病杂志. 2025(01): 153-161 .
    3. 张磊，乐偲，刘岩，陈丽萌. 遗传性罕见肾脏病：精准肾脏病学的窗口. 罕见病研究. 2024(01): 1-11 .
    4. 陈丽萌，陈朝英，张抒扬，张磊，彭晓艳，杨宏仙，简珊，樊晓红，蒋兰萍，董源，赵若环，吕宁，乐偲，涂娟. Bartter综合征诊疗中国专家共识(2023). 罕见病研究. 2024(01): 87-101 .
    5. 周冬祺，唐诗韵，陈秋. SLC12A3基因新型纯合突变导致的Gitelman综合征合并2型糖尿病家系追踪. 中华糖尿病杂志. 2024(02): 248-253 .
    6. 陈蓉，王曦，宋桉，王佳佳，李伟，陈适，邢小平. 青年女性，乏力，低血钾，高血糖. 协和医学杂志. 2024(02): 456-461 . 本站查看
    7. 张洪旭，李娟娟，程炳菲，辛颖. Gitelman综合征合并库欣病1例并文献复习. 临床肾脏病杂志. 2024(04): 349-352 .
    8. 何敏，吴加华，刘剑，赵延栋，王云卿，吴君平. Gitelman综合征合并下颌肿物1例并文献复习. 中国乡村医药. 2024(11): 51-52 .
    9. 马韩铮，杨玲玲，刘栋，李岩. 扶阳建中针刺法治疗以矮身材为主要表现的Gitelman综合征1例. 中医儿科杂志. 2024(04): 89-91 .
    10. 葛丹，胡雪剑. Gitelman综合征合并抑郁症1例. 中国医药科学. 2024(16): 188-190 .
    11. 林彦琳，毕丽妨，王珏. 单等位 SLC12A3基因突变致Gitelman综合征1例的遗传学分析. 国际遗传学杂志. 2024(05): 361-365 .
    12. 周奇，李沁原，刘雅莉，罗征秀，张卫社，陈彤，李国保，商洪才，杨克虎，张波，陈耀龙，张抒扬. 罕见病指南的制订：现状、挑战与机遇. 协和医学杂志. 2023(03): 621-628 . 本站查看
    13. 穆妮热·阿塔吾拉，郭艳英. Gitelman综合征并发症及常见合并症的研究进展. 医学研究杂志. 2023(05): 177-179+114 .
    14. 陈杰梅，郑跃杰，高晓洁，南晓娟. 儿童Gitelman综合征的临床特征、基因型及预后分析. 国际医药卫生导报. 2023(13): 1850-1856 .
    15. 朱惠娟，卢琳，张晓波，吕晓虹，张丁月，陈适. 双侧岩下窦静脉采血在库欣综合征诊断中应用的专家共识(2023). 罕见病研究. 2023(03): 365-376 .
    16. 穆妮热·阿塔吾拉，马福慧，张凯迪，王新玲，郭艳英. 2011-2020年新疆某三甲医院低钾血症病因构成及血钾特点分析. 新疆医学. 2023(06): 639-642+669 .
    17. 阚路兰，田茂强，唐一蜜. 以腹痛为首发症状的轻型Gitelman综合征患儿1例及文献复习. 中华妇幼临床医学杂志(电子版). 2023(04): 473-479 .
    18. 李雪峰，韩宾宾，王善龙，姜卫波，彭慧芳，姜宏卫. 不同伴随症的Gitelman综合征的诊治研究. 临床医学. 2023(11): 1-4 .
    19. 阮希成，朱荣杰，蔡奕琪，郑浩，林程，陈宏斌. 妊娠合并Gitelman综合征1例. 福建医科大学学报. 2023(05): 380-382 .
    20. 李文文，鲁瑾. Gitelman综合征伴胰岛素抵抗1例. 中华糖尿病杂志. 2023(Z1): 96-98 .
    21. 陈甜甜，王晓东，余海燕. 双胎妊娠合并Gitelman综合征孕妇的妊娠结局及文献复习. 中华妇幼临床医学杂志(电子版). 2023(05): 559-568 .
    22. 赵喆，唐彦，周婧雅，陈晓光，张磊，陈丽萌，袁涛. 50例Gitelman综合征患者临床特征和药物治疗分析. 协和医学杂志. 2022(02): 277-286 . 本站查看
    23. 谢容融，金萍，杨幼波，张勤，熊静. 全外显子组测序诊断2例Gitelman综合征. 中南大学学报(医学版). 2022(03): 401-406 .
    24. 陈正，吴娟，邱瑜，刘建萍. Gitelman综合征伴2型糖尿病一例报道. 中国糖尿病杂志. 2022(05): 370-374 .
    25. 李敏，黄稳莹，张甜，郭英. 1例Gitelman综合征合并亚临床甲状腺功能减退症患者SLC12A3基因突变位点鉴定及遗传分析. 山东医药. 2022(15): 86-89 .
    26. 朱凯瑞，李霞，李晓岚. 从1例Gitelman综合征探讨低钾血症的全科诊疗思路. 巴楚医学. 2022(02): 14-17 .
    27. 甘佳乐，刘超，方亮娟. SLC12A3基因突变致Gitelman综合征1例. 国际遗传学杂志. 2022(06): 499-502 .
    28. 仝天，王瑞英，张力辉，刘志红，骆建芹，赵占胜. 血镁正常的Gitelman综合征1例及文献复习. 临床荟萃. 2022(11): 1031-1036 .

    Other cited types(4)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (239) PDF downloads (82) Cited by(32)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close